Table 1

Baseline characteristics for participants in the Swiss HIV cohort study on HAART and those in the analysis who did not reach the primary endpoint. Values are numbers (percentages) unless stated otherwise

Cohort members on HAARTDid not reach primary endpoint
CharacteristicIncluded in analysis (n=3736)Excluded (n=1614)Attended follow up (n=2896)Not followed up (n=413)
Median viral load (log10 copies/ml)4.504.454.47
Median CD4 cell count (cells/μl)210222252
Median age (years)36363635
Sex:
Female1096 (29)474 (29)864 (30)123 (30)
Male2640 (71)1140 (71)2032 (70)290 (70)
Transmission group:
Homosexual1295 (35)538 (33)1076 (37)87 (21)
Intravenous drug user1077 (29)464 (29)724 (25)186 (45)
Heterosexual, other, or unknown1364 (37)612 (38)1096 (38)140 (34)
Education:
Higher2532 (68)1026 (64)2003 (69)245 (59)
Basic or unknown1204 (32)588 (36)893 (31)168 (41)
Ethnicity:
Other than white European392 (10)214 (13)315 (11)50 (12)
White European or unknown3340 (90)1400 (87)2581 (89)363 (88)
Clinical stage:
A1670 (45)718 (44)1374 (47)189 (46)
B1173 (31)426 (26)891 (31)130 (31)
C893 (24)470 (29)631 (22)94 (23)
Previous antiretroviral therapy:
No1912 (51)890 (55)1522 (53)203 (49)
Yes1824 (49)724 (45)1374 (47)210 (51)
If yes, median duration (years)1.71.61.71.7

HAART=highly active antiretroviral therapy.

  • * During the 12 months before 28 February 2002.

  • † Transmission through blood products or perinatal transmission.